+关注
V meng
暂无个人介绍
IP属地：福建
33
关注
0
粉丝
0
主题
0
勋章
主贴
热门
V meng
05-24
$20+年以上美国国债ETF-iShares(TLT)$
V meng
05-24
这篇文章不错，转发给大家看看
@小贝导演:
$恒瑞医药(01276)$
全麻手术结束以后，第一眼看股票，两个医疗股全大涨，我就放心了
$MIRXES-B(02629)$
V meng
03-23
$趣致集团(00917)$
V meng
03-20
$英伟达(NVDA)$
V meng
03-15
这篇文章不错，转发给大家看看
@小金历险记:维升药业赴港IPO：能否复制港股医药股逆袭神话？
V meng
03-08
这篇文章不错，转发给大家看看
@AaronHy:
$特斯拉(TSLA)$
$英伟达(NVDA)$
$苹果(AAPL)$
30w 半个月不到150w 今晚期权买call 今日操作见图二 欢迎关注 早关注的已经赚麻了[开心]
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4204250543704742","uuid":"4204250543704742","gmtCreate":1741147366047,"gmtModify":1741152809524,"name":"V meng","pinyin":"vmengvmeng","introduction":"","introductionEn":null,"signature":"","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":33,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":1,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[],"userBadgeCount":0,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"福建","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":25,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":438213284438848,"gmtCreate":1748020620331,"gmtModify":1748020768828,"author":{"id":"4204250543704742","authorId":"4204250543704742","name":"V meng","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4204250543704742","authorIdStr":"4204250543704742"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TLT\">$20+年以上美国国债ETF-iShares(TLT)$ </a> ","listText":"<a href=\"https://laohu8.com/S/TLT\">$20+年以上美国国债ETF-iShares(TLT)$ </a> ","text":"$20+年以上美国国债ETF-iShares(TLT)$","images":[{"img":"https://static.tigerbbs.com/c0c0e56237d4a118c4b9dc57e142bb89","width":"1284","height":"2040"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/438213284438848","isVote":1,"tweetType":1,"viewCount":533,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":438212442689872,"gmtCreate":1748020557103,"gmtModify":1748020558932,"author":{"id":"4204250543704742","authorId":"4204250543704742","name":"V meng","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4204250543704742","authorIdStr":"4204250543704742"},"themes":[],"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/438212442689872","repostId":"437790425751776","repostType":1,"repost":{"id":437790425751776,"gmtCreate":1747906630727,"gmtModify":1747966283541,"author":{"id":"3505175992816849","authorId":"3505175992816849","name":"小贝导演","avatar":"https://static.tigerbbs.com/4b2d014b4fa5c9fc7eef14677fed5aca","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3505175992816849","authorIdStr":"3505175992816849"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01276\">$恒瑞医药(01276)$</a> 全麻手术结束以后，第一眼看股票，两个医疗股全大涨，我就放心了<a href=\"https://laohu8.com/S/02629\">$MIRXES-B(02629)$</a> ","listText":"<a href=\"https://laohu8.com/S/01276\">$恒瑞医药(01276)$</a> 全麻手术结束以后，第一眼看股票，两个医疗股全大涨，我就放心了<a href=\"https://laohu8.com/S/02629\">$MIRXES-B(02629)$</a> ","text":"$恒瑞医药(01276)$ 全麻手术结束以后，第一眼看股票，两个医疗股全大涨，我就放心了$MIRXES-B(02629)$","images":[{"img":"https://static.tigerbbs.com/aff35d267e080d7d886f792b3bfa05df","width":"1086","height":"1713"},{"img":"https://static.tigerbbs.com/514835d24db5bdd2234c5450cc86e2d8","width":"3024","height":"4032"},{"img":"https://static.tigerbbs.com/944ebb7a22a00c7743c524f05d294c71","width":"3024","height":"4032"}],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/437790425751776","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":242,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":416385276543224,"gmtCreate":1742665180846,"gmtModify":1742692628841,"author":{"id":"4204250543704742","authorId":"4204250543704742","name":"V meng","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4204250543704742","authorIdStr":"4204250543704742"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/00917\">$趣致集团(00917)$</a> ","listText":"<a href=\"https://laohu8.com/S/00917\">$趣致集团(00917)$</a> ","text":"$趣致集团(00917)$","images":[{"img":"https://static.tigerbbs.com/1d60d2f91f14f6102b74bbd585b38317","width":"1284","height":"1746"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/416385276543224","isVote":1,"tweetType":1,"viewCount":475,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":415277169439192,"gmtCreate":1742405856417,"gmtModify":1742420316511,"author":{"id":"4204250543704742","authorId":"4204250543704742","name":"V meng","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4204250543704742","authorIdStr":"4204250543704742"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$ </a> ","listText":"<a href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$ </a> ","text":"$英伟达(NVDA)$","images":[{"img":"https://static.tigerbbs.com/21ff203423f751b97516d4521afdccdf","width":"1284","height":"1932"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/415277169439192","isVote":1,"tweetType":1,"viewCount":639,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":413457948295400,"gmtCreate":1741971204945,"gmtModify":1741972246459,"author":{"id":"4204250543704742","authorId":"4204250543704742","name":"V meng","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4204250543704742","authorIdStr":"4204250543704742"},"themes":[],"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/413457948295400","repostId":"413425809088712","repostType":1,"repost":{"id":413425809088712,"gmtCreate":1741963345268,"gmtModify":1741963781265,"author":{"id":"3545362064796184","authorId":"3545362064796184","name":"小金历险记","avatar":"https://static.tigerbbs.com/8587473a2225fadefc934e61ecd3d7f8","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3545362064796184","authorIdStr":"3545362064796184"},"themes":[],"title":"维升药业赴港IPO：能否复制港股医药股逆袭神话？","htmlText":"一、公司定位：内分泌赛道的“技术黑马” 维升药业（02561.HK）成立于2018年，专注于内分泌疾病创新疗法研发，核心产品包括全球首个优效于日制剂的长效生长激素隆培促生长素（已提交中国上市申请），以及两款处于临床后期的突破性药物。公司依托丹麦Ascendis Pharma的TransCon长效技术平台，通过“暂时连接”分子设计延长药物半衰期，解决传统激素治疗需频繁注射的痛点，覆盖生长激素缺乏症、甲状旁腺功能减退症等适应症。 差异化优势： 技术壁垒：TransCon平台已获欧美药监局认可，隆培促生长素海外销售额达1.97亿欧元（2024年） 管线稀缺性：国内唯一针对软骨发育不全病因的那韦培肽，潜在填补50亿市场空白 商业化加速：上海、苏州生产基地已投产，B轮融资后估值超10亿美元 二、赛道潜力：非糖尿病内分泌市场的“隐形金矿” 中国内分泌药物市场呈现“一超多强”格局：糖尿病药物占据80%份额，而生长激素、甲状旁腺疾病等细分领域增速达15%-20%，2030年规模预计突破740亿元。 维升药业避开内卷的肿瘤赛道，主攻三大蓝海领域： 生长激素市场：长春高新垄断75%份额，但长效剂型渗透率仅30%（vs 欧美60%），隆培促生长素的每周一次注射优势显著 甲状旁腺功能减退症：国内尚无替代疗法，帕罗培特立帕肽作为全球首个FIC药物，3期试验达标 软骨发育不全：患者约9万人，现有疗法仅缓解症状，那韦培肽可靶向FGFR3通路 三、打新亮点：高胜率要素拆解 行业热度：医药股2024年港股打新首日平均涨幅28%（vs 全市场19%），生物医药占超购TOP10的40% 市场热度：蜜雪集团，毛戈平，老铺黄金次新股大涨，中概腾讯，小米，阿里巴巴也引领一波上涨 保荐人：摩根士丹利+富瑞金融保荐，大摩稳价会出一点力，如果大跌他会装死 估值锚定：发行价对应PE 32倍，较长春高新（45倍）折价29%，较","listText":"一、公司定位：内分泌赛道的“技术黑马” 维升药业（02561.HK）成立于2018年，专注于内分泌疾病创新疗法研发，核心产品包括全球首个优效于日制剂的长效生长激素隆培促生长素（已提交中国上市申请），以及两款处于临床后期的突破性药物。公司依托丹麦Ascendis Pharma的TransCon长效技术平台，通过“暂时连接”分子设计延长药物半衰期，解决传统激素治疗需频繁注射的痛点，覆盖生长激素缺乏症、甲状旁腺功能减退症等适应症。 差异化优势： 技术壁垒：TransCon平台已获欧美药监局认可，隆培促生长素海外销售额达1.97亿欧元（2024年） 管线稀缺性：国内唯一针对软骨发育不全病因的那韦培肽，潜在填补50亿市场空白 商业化加速：上海、苏州生产基地已投产，B轮融资后估值超10亿美元 二、赛道潜力：非糖尿病内分泌市场的“隐形金矿” 中国内分泌药物市场呈现“一超多强”格局：糖尿病药物占据80%份额，而生长激素、甲状旁腺疾病等细分领域增速达15%-20%，2030年规模预计突破740亿元。 维升药业避开内卷的肿瘤赛道，主攻三大蓝海领域： 生长激素市场：长春高新垄断75%份额，但长效剂型渗透率仅30%（vs 欧美60%），隆培促生长素的每周一次注射优势显著 甲状旁腺功能减退症：国内尚无替代疗法，帕罗培特立帕肽作为全球首个FIC药物，3期试验达标 软骨发育不全：患者约9万人，现有疗法仅缓解症状，那韦培肽可靶向FGFR3通路 三、打新亮点：高胜率要素拆解 行业热度：医药股2024年港股打新首日平均涨幅28%（vs 全市场19%），生物医药占超购TOP10的40% 市场热度：蜜雪集团，毛戈平，老铺黄金次新股大涨，中概腾讯，小米，阿里巴巴也引领一波上涨 保荐人：摩根士丹利+富瑞金融保荐，大摩稳价会出一点力，如果大跌他会装死 估值锚定：发行价对应PE 32倍，较长春高新（45倍）折价29%，较","text":"一、公司定位：内分泌赛道的“技术黑马” 维升药业（02561.HK）成立于2018年，专注于内分泌疾病创新疗法研发，核心产品包括全球首个优效于日制剂的长效生长激素隆培促生长素（已提交中国上市申请），以及两款处于临床后期的突破性药物。公司依托丹麦Ascendis Pharma的TransCon长效技术平台，通过“暂时连接”分子设计延长药物半衰期，解决传统激素治疗需频繁注射的痛点，覆盖生长激素缺乏症、甲状旁腺功能减退症等适应症。 差异化优势： 技术壁垒：TransCon平台已获欧美药监局认可，隆培促生长素海外销售额达1.97亿欧元（2024年） 管线稀缺性：国内唯一针对软骨发育不全病因的那韦培肽，潜在填补50亿市场空白 商业化加速：上海、苏州生产基地已投产，B轮融资后估值超10亿美元 二、赛道潜力：非糖尿病内分泌市场的“隐形金矿” 中国内分泌药物市场呈现“一超多强”格局：糖尿病药物占据80%份额，而生长激素、甲状旁腺疾病等细分领域增速达15%-20%，2030年规模预计突破740亿元。 维升药业避开内卷的肿瘤赛道，主攻三大蓝海领域： 生长激素市场：长春高新垄断75%份额，但长效剂型渗透率仅30%（vs 欧美60%），隆培促生长素的每周一次注射优势显著 甲状旁腺功能减退症：国内尚无替代疗法，帕罗培特立帕肽作为全球首个FIC药物，3期试验达标 软骨发育不全：患者约9万人，现有疗法仅缓解症状，那韦培肽可靶向FGFR3通路 三、打新亮点：高胜率要素拆解 行业热度：医药股2024年港股打新首日平均涨幅28%（vs 全市场19%），生物医药占超购TOP10的40% 市场热度：蜜雪集团，毛戈平，老铺黄金次新股大涨，中概腾讯，小米，阿里巴巴也引领一波上涨 保荐人：摩根士丹利+富瑞金融保荐，大摩稳价会出一点力，如果大跌他会装死 估值锚定：发行价对应PE 32倍，较长春高新（45倍）折价29%，较","images":[],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/413425809088712","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":794,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":410964713423480,"gmtCreate":1741366287389,"gmtModify":1741366999540,"author":{"id":"4204250543704742","authorId":"4204250543704742","name":"V meng","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4204250543704742","authorIdStr":"4204250543704742"},"themes":[],"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/410964713423480","repostId":"410537310495072","repostType":1,"repost":{"id":410537310495072,"gmtCreate":1741251615235,"gmtModify":1741255804583,"author":{"id":"3586347563730096","authorId":"3586347563730096","name":"AaronHy","avatar":"https://static.tigerbbs.com/45108470b279fe06f75566e2a9699141","crmLevel":9,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3586347563730096","authorIdStr":"3586347563730096"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$ </a><v-v data-views=\"1\"></v-v> <a href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$ </a><v-v data-views=\"1\"></v-v> <a href=\"https://laohu8.com/S/AAPL\">$苹果(AAPL)$ </a><v-v data-views=\"1\"></v-v> 30w 半个月不到150w 今晚期权买call 今日操作见图二 欢迎关注 早关注的已经赚麻了[开心] ","listText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$ </a><v-v data-views=\"1\"></v-v> <a href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$ </a><v-v data-views=\"1\"></v-v> <a href=\"https://laohu8.com/S/AAPL\">$苹果(AAPL)$ </a><v-v data-views=\"1\"></v-v> 30w 半个月不到150w 今晚期权买call 今日操作见图二 欢迎关注 早关注的已经赚麻了[开心] ","text":"$特斯拉(TSLA)$ $英伟达(NVDA)$ $苹果(AAPL)$ 30w 半个月不到150w 今晚期权买call 今日操作见图二 欢迎关注 早关注的已经赚麻了[开心]","images":[{"img":"https://static.tigerbbs.com/8b3d7c191bc469d3197aea25d5b266d2","width":"1179","height":"2556"},{"img":"https://static.tigerbbs.com/69c649566b10150f213ce9d56bb133aa","width":"1179","height":"2556"},{"img":"https://static.tigerbbs.com/c2a134649df3d281ce913c199f9c8704","width":"1179","height":"2556"}],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/410537310495072","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1204,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":438213284438848,"gmtCreate":1748020620331,"gmtModify":1748020768828,"author":{"id":"4204250543704742","authorId":"4204250543704742","name":"V meng","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4204250543704742","idStr":"4204250543704742"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TLT\">$20+年以上美国国债ETF-iShares(TLT)$ </a> ","listText":"<a href=\"https://laohu8.com/S/TLT\">$20+年以上美国国债ETF-iShares(TLT)$ </a> ","text":"$20+年以上美国国债ETF-iShares(TLT)$","images":[{"img":"https://static.tigerbbs.com/c0c0e56237d4a118c4b9dc57e142bb89","width":"1284","height":"2040"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/438213284438848","isVote":1,"tweetType":1,"viewCount":533,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":438212442689872,"gmtCreate":1748020557103,"gmtModify":1748020558932,"author":{"id":"4204250543704742","authorId":"4204250543704742","name":"V meng","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4204250543704742","idStr":"4204250543704742"},"themes":[],"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/438212442689872","repostId":"437790425751776","repostType":1,"repost":{"id":437790425751776,"gmtCreate":1747906630727,"gmtModify":1747966283541,"author":{"id":"3505175992816849","authorId":"3505175992816849","name":"小贝导演","avatar":"https://static.tigerbbs.com/4b2d014b4fa5c9fc7eef14677fed5aca","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3505175992816849","idStr":"3505175992816849"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01276\">$恒瑞医药(01276)$</a> 全麻手术结束以后，第一眼看股票，两个医疗股全大涨，我就放心了<a href=\"https://laohu8.com/S/02629\">$MIRXES-B(02629)$</a> ","listText":"<a href=\"https://laohu8.com/S/01276\">$恒瑞医药(01276)$</a> 全麻手术结束以后，第一眼看股票，两个医疗股全大涨，我就放心了<a href=\"https://laohu8.com/S/02629\">$MIRXES-B(02629)$</a> ","text":"$恒瑞医药(01276)$ 全麻手术结束以后，第一眼看股票，两个医疗股全大涨，我就放心了$MIRXES-B(02629)$","images":[{"img":"https://static.tigerbbs.com/aff35d267e080d7d886f792b3bfa05df","width":"1086","height":"1713"},{"img":"https://static.tigerbbs.com/514835d24db5bdd2234c5450cc86e2d8","width":"3024","height":"4032"},{"img":"https://static.tigerbbs.com/944ebb7a22a00c7743c524f05d294c71","width":"3024","height":"4032"}],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/437790425751776","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":242,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":416385276543224,"gmtCreate":1742665180846,"gmtModify":1742692628841,"author":{"id":"4204250543704742","authorId":"4204250543704742","name":"V meng","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4204250543704742","idStr":"4204250543704742"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/00917\">$趣致集团(00917)$</a> ","listText":"<a href=\"https://laohu8.com/S/00917\">$趣致集团(00917)$</a> ","text":"$趣致集团(00917)$","images":[{"img":"https://static.tigerbbs.com/1d60d2f91f14f6102b74bbd585b38317","width":"1284","height":"1746"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/416385276543224","isVote":1,"tweetType":1,"viewCount":475,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":415277169439192,"gmtCreate":1742405856417,"gmtModify":1742420316511,"author":{"id":"4204250543704742","authorId":"4204250543704742","name":"V meng","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4204250543704742","idStr":"4204250543704742"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$ </a> ","listText":"<a href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$ </a> ","text":"$英伟达(NVDA)$","images":[{"img":"https://static.tigerbbs.com/21ff203423f751b97516d4521afdccdf","width":"1284","height":"1932"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/415277169439192","isVote":1,"tweetType":1,"viewCount":639,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":413457948295400,"gmtCreate":1741971204945,"gmtModify":1741972246459,"author":{"id":"4204250543704742","authorId":"4204250543704742","name":"V meng","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4204250543704742","idStr":"4204250543704742"},"themes":[],"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/413457948295400","repostId":"413425809088712","repostType":1,"repost":{"id":413425809088712,"gmtCreate":1741963345268,"gmtModify":1741963781265,"author":{"id":"3545362064796184","authorId":"3545362064796184","name":"小金历险记","avatar":"https://static.tigerbbs.com/8587473a2225fadefc934e61ecd3d7f8","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3545362064796184","idStr":"3545362064796184"},"themes":[],"title":"维升药业赴港IPO：能否复制港股医药股逆袭神话？","htmlText":"一、公司定位：内分泌赛道的“技术黑马” 维升药业（02561.HK）成立于2018年，专注于内分泌疾病创新疗法研发，核心产品包括全球首个优效于日制剂的长效生长激素隆培促生长素（已提交中国上市申请），以及两款处于临床后期的突破性药物。公司依托丹麦Ascendis Pharma的TransCon长效技术平台，通过“暂时连接”分子设计延长药物半衰期，解决传统激素治疗需频繁注射的痛点，覆盖生长激素缺乏症、甲状旁腺功能减退症等适应症。 差异化优势： 技术壁垒：TransCon平台已获欧美药监局认可，隆培促生长素海外销售额达1.97亿欧元（2024年） 管线稀缺性：国内唯一针对软骨发育不全病因的那韦培肽，潜在填补50亿市场空白 商业化加速：上海、苏州生产基地已投产，B轮融资后估值超10亿美元 二、赛道潜力：非糖尿病内分泌市场的“隐形金矿” 中国内分泌药物市场呈现“一超多强”格局：糖尿病药物占据80%份额，而生长激素、甲状旁腺疾病等细分领域增速达15%-20%，2030年规模预计突破740亿元。 维升药业避开内卷的肿瘤赛道，主攻三大蓝海领域： 生长激素市场：长春高新垄断75%份额，但长效剂型渗透率仅30%（vs 欧美60%），隆培促生长素的每周一次注射优势显著 甲状旁腺功能减退症：国内尚无替代疗法，帕罗培特立帕肽作为全球首个FIC药物，3期试验达标 软骨发育不全：患者约9万人，现有疗法仅缓解症状，那韦培肽可靶向FGFR3通路 三、打新亮点：高胜率要素拆解 行业热度：医药股2024年港股打新首日平均涨幅28%（vs 全市场19%），生物医药占超购TOP10的40% 市场热度：蜜雪集团，毛戈平，老铺黄金次新股大涨，中概腾讯，小米，阿里巴巴也引领一波上涨 保荐人：摩根士丹利+富瑞金融保荐，大摩稳价会出一点力，如果大跌他会装死 估值锚定：发行价对应PE 32倍，较长春高新（45倍）折价29%，较","listText":"一、公司定位：内分泌赛道的“技术黑马” 维升药业（02561.HK）成立于2018年，专注于内分泌疾病创新疗法研发，核心产品包括全球首个优效于日制剂的长效生长激素隆培促生长素（已提交中国上市申请），以及两款处于临床后期的突破性药物。公司依托丹麦Ascendis Pharma的TransCon长效技术平台，通过“暂时连接”分子设计延长药物半衰期，解决传统激素治疗需频繁注射的痛点，覆盖生长激素缺乏症、甲状旁腺功能减退症等适应症。 差异化优势： 技术壁垒：TransCon平台已获欧美药监局认可，隆培促生长素海外销售额达1.97亿欧元（2024年） 管线稀缺性：国内唯一针对软骨发育不全病因的那韦培肽，潜在填补50亿市场空白 商业化加速：上海、苏州生产基地已投产，B轮融资后估值超10亿美元 二、赛道潜力：非糖尿病内分泌市场的“隐形金矿” 中国内分泌药物市场呈现“一超多强”格局：糖尿病药物占据80%份额，而生长激素、甲状旁腺疾病等细分领域增速达15%-20%，2030年规模预计突破740亿元。 维升药业避开内卷的肿瘤赛道，主攻三大蓝海领域： 生长激素市场：长春高新垄断75%份额，但长效剂型渗透率仅30%（vs 欧美60%），隆培促生长素的每周一次注射优势显著 甲状旁腺功能减退症：国内尚无替代疗法，帕罗培特立帕肽作为全球首个FIC药物，3期试验达标 软骨发育不全：患者约9万人，现有疗法仅缓解症状，那韦培肽可靶向FGFR3通路 三、打新亮点：高胜率要素拆解 行业热度：医药股2024年港股打新首日平均涨幅28%（vs 全市场19%），生物医药占超购TOP10的40% 市场热度：蜜雪集团，毛戈平，老铺黄金次新股大涨，中概腾讯，小米，阿里巴巴也引领一波上涨 保荐人：摩根士丹利+富瑞金融保荐，大摩稳价会出一点力，如果大跌他会装死 估值锚定：发行价对应PE 32倍，较长春高新（45倍）折价29%，较","text":"一、公司定位：内分泌赛道的“技术黑马” 维升药业（02561.HK）成立于2018年，专注于内分泌疾病创新疗法研发，核心产品包括全球首个优效于日制剂的长效生长激素隆培促生长素（已提交中国上市申请），以及两款处于临床后期的突破性药物。公司依托丹麦Ascendis Pharma的TransCon长效技术平台，通过“暂时连接”分子设计延长药物半衰期，解决传统激素治疗需频繁注射的痛点，覆盖生长激素缺乏症、甲状旁腺功能减退症等适应症。 差异化优势： 技术壁垒：TransCon平台已获欧美药监局认可，隆培促生长素海外销售额达1.97亿欧元（2024年） 管线稀缺性：国内唯一针对软骨发育不全病因的那韦培肽，潜在填补50亿市场空白 商业化加速：上海、苏州生产基地已投产，B轮融资后估值超10亿美元 二、赛道潜力：非糖尿病内分泌市场的“隐形金矿” 中国内分泌药物市场呈现“一超多强”格局：糖尿病药物占据80%份额，而生长激素、甲状旁腺疾病等细分领域增速达15%-20%，2030年规模预计突破740亿元。 维升药业避开内卷的肿瘤赛道，主攻三大蓝海领域： 生长激素市场：长春高新垄断75%份额，但长效剂型渗透率仅30%（vs 欧美60%），隆培促生长素的每周一次注射优势显著 甲状旁腺功能减退症：国内尚无替代疗法，帕罗培特立帕肽作为全球首个FIC药物，3期试验达标 软骨发育不全：患者约9万人，现有疗法仅缓解症状，那韦培肽可靶向FGFR3通路 三、打新亮点：高胜率要素拆解 行业热度：医药股2024年港股打新首日平均涨幅28%（vs 全市场19%），生物医药占超购TOP10的40% 市场热度：蜜雪集团，毛戈平，老铺黄金次新股大涨，中概腾讯，小米，阿里巴巴也引领一波上涨 保荐人：摩根士丹利+富瑞金融保荐，大摩稳价会出一点力，如果大跌他会装死 估值锚定：发行价对应PE 32倍，较长春高新（45倍）折价29%，较","images":[],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/413425809088712","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":794,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":410964713423480,"gmtCreate":1741366287389,"gmtModify":1741366999540,"author":{"id":"4204250543704742","authorId":"4204250543704742","name":"V meng","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4204250543704742","idStr":"4204250543704742"},"themes":[],"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/410964713423480","repostId":"410537310495072","repostType":1,"repost":{"id":410537310495072,"gmtCreate":1741251615235,"gmtModify":1741255804583,"author":{"id":"3586347563730096","authorId":"3586347563730096","name":"AaronHy","avatar":"https://static.tigerbbs.com/45108470b279fe06f75566e2a9699141","crmLevel":9,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3586347563730096","idStr":"3586347563730096"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$ </a><v-v data-views=\"1\"></v-v> <a href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$ </a><v-v data-views=\"1\"></v-v> <a href=\"https://laohu8.com/S/AAPL\">$苹果(AAPL)$ </a><v-v data-views=\"1\"></v-v> 30w 半个月不到150w 今晚期权买call 今日操作见图二 欢迎关注 早关注的已经赚麻了[开心] ","listText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$ </a><v-v data-views=\"1\"></v-v> <a href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$ </a><v-v data-views=\"1\"></v-v> <a href=\"https://laohu8.com/S/AAPL\">$苹果(AAPL)$ </a><v-v data-views=\"1\"></v-v> 30w 半个月不到150w 今晚期权买call 今日操作见图二 欢迎关注 早关注的已经赚麻了[开心] ","text":"$特斯拉(TSLA)$ $英伟达(NVDA)$ $苹果(AAPL)$ 30w 半个月不到150w 今晚期权买call 今日操作见图二 欢迎关注 早关注的已经赚麻了[开心]","images":[{"img":"https://static.tigerbbs.com/8b3d7c191bc469d3197aea25d5b266d2","width":"1179","height":"2556"},{"img":"https://static.tigerbbs.com/69c649566b10150f213ce9d56bb133aa","width":"1179","height":"2556"},{"img":"https://static.tigerbbs.com/c2a134649df3d281ce913c199f9c8704","width":"1179","height":"2556"}],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/410537310495072","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1204,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
